Bausch & Lomb bags eyeonics

Article

Bausch & Lomb has acquired eyeonics, the maker of the crystalens accommodating IOL.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Related Content
A computer screen with a lit-up brain on it. The computer is in a laboratory. Concept image of AI artificial intelligence use in glaucoma diagnosis and treatment.

Feasibility of artificial intelligence in leading glaucoma care

Lynda Charters
August 7th 2025
Article
Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
August 7th 2025
Podcast
An image of the planet Earth encircled by a DNA strand. Concept image for global inherited retinal disease research collaboration, Opus Genetics and RDH12 alliance. Image credit: ©JohanSwanepoel – stock.adobe.com

Opus Genetics, Global RDH12 Alliance announce new collaboration

Kassi Filkins
August 7th 2025
Article
Logos for Topcon Healthcare (left, black and purple) and Intelligent Retinal Imaging Systems (IRIS, right, blue and green). Concept image for diabetic eye disease retina screening company merger. Image courtesy of Topcon Healthcare.

Topcon expands AI portfolio with Intelligent Retinal Imaging Systems acquisition

Hattie Hayes
August 7th 2025
Article
Exonate announces CLEAR-DE trial for EXN407

Exonate announces CLEAR-DE trial for EXN407

Kassi Filkins
August 7th 2025
Article
Two people sit at a table. Their hands are visible, as are computers, pencils, notebooks, clipboards and documents. Concept image for business merger, licensing partnership, work collaboration, commercialisation throughout Europe, Re-Vana Therapeutics and Boehringer Ingelheim ocular eye drug therapy. Image credit: ©NAMPIX – stock.adobe.com

Re-Vana Therapeutics and Boehringer Ingelheim announce collaboration, licensing partnership

Lynda Charters
August 7th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.